Navigation Links
Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
Date:1/8/2008

SAN CARLOS, Calif., Jan. 8 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced the start of its Phase 2 clinical development program to evaluate NKTR-102 (PEG-irinotecan) as a potential treatment for colorectal cancer. NKTR-102 is Nektar's lead oncolytic candidate using the company's innovative small molecule PEGylation technology platform.

"The start of the Phase 2 program for NKTR-102 in colorectal cancer is a major achievement for Nektar," said Howard W. Robin, Nektar President and Chief Executive Officer. "Our Phase 2 program has the potential to demonstrate Nektar's ability to generate innovative and important PEGylated small molecule therapeutics. Based on our positive Phase 1 study findings, we also plan to initiate Phase 2 studies this year to evaluate NKTR-102 in multiple solid tumor settings."

Results from the Phase 1 study for NKTR-102 are expected to be presented at major oncology conferences in 2008.

About the Phase 2 Clinical Development Program for NKTR-102 (PEG-irinotecan)

The Phase 2 program is designed to evaluate the safety and efficacy of NKTR-102 (PEG-irinotecan) for the treatment of patients with solid tumors. The first study in the program will investigate NKTR-102 in combination with cetuximab as a second-line colorectal cancer treatment in irinotecan-naive patients as compared to treatment with standard irinotecan in combination with cetuximab.

The colorectal study is comprised of two sequential stages. The Phase 2a is an open-label, dose-finding trial in multiple solid tumor types that are refractory to standard curative or palliative therapies. The Phase 2b is an open-label, randomized, double-arm study in patients with second-line metastatic colorectal
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Memory Pharmaceuticals Commences Phase 1 Clinical Program for R4996/MEM 63908
2. Sinovac Commences Vaccination on Volunteers for Phase II Clinical Trial on Pandemic Influenza H5N1 Vaccine
3. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
4. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
5. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
6. EntreMed Commences Phase 2 Study with MKC-1 in Pancreatic Cancer
7. Alexion Commences Dosing in AEGIS Registration Study of Soliris(R) (eculizumab) in Patients with PNH in Japan
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
10. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
11. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)... , CHICAGO, Nov. 30 MedPro I...ultrasound solutions, will showcase leading ultras... Logiq I and Siemens X300 Premium Edition during t...f North America (RSNA) conference, being held in C...ased MedPro Imaging markets ultrasound products an...
(Date:11/30/2009)... , CHICAGO, Nov. 30 Minim...g more costly open surgery, particularly in oncolo...ith a global market for image-guided navigation ex...re embracing the advantages offered by minimally-i...very times, greater patient comfort and faster pat...
(Date:11/30/2009)... , WAYNE, N.J. and CHICAGO, Nov. 30 /PRNewswi...nnual Meeting of the Radiological Society of Nor...s Inc. announced the enrollment of the first patie... evaluate the efficacy and safety of florbetaben (...Amyloid plaques in the brain, which are a patholog...
Breaking Medicine Technology:MedPro Imaging to Showcase Leading New and Refurbished Ultrasound Solutions at RSNA 2Philips Showcases Interventional Radiology Solutions to Support Growing Need For Minimally-Invasive Procedures 2Philips Showcases Interventional Radiology Solutions to Support Growing Need For Minimally-Invasive Procedures 3Philips Showcases Interventional Radiology Solutions to Support Growing Need For Minimally-Invasive Procedures 4Philips Showcases Interventional Radiology Solutions to Support Growing Need For Minimally-Invasive Procedures 5Bayer HealthCare Pharmaceuticals Initiates Phase III Trial with Florbetaben PET Tracer for Imaging of Cerebral beta-Amyloid Plaques, a Pathological Hallmark of Alzheimer's Disease 2Bayer HealthCare Pharmaceuticals Initiates Phase III Trial with Florbetaben PET Tracer for Imaging of Cerebral beta-Amyloid Plaques, a Pathological Hallmark of Alzheimer's Disease 3DOR BioPharma Announces Issuance of European Patent for its LPM 28TM 29 Oral Drug Delivery Technology 12934 1DOR BioPharma Announces Issuance of European Patent for its LPM 28TM 29 Oral Drug Delivery Technology 12934 2DOR BioPharma Announces Issuance of European Patent for its LPM 28TM 29 Oral Drug Delivery Technology 12934 3DOR BioPharma Announces Issuance of European Patent for its LPM 28TM 29 Oral Drug Delivery Technology 12934 4DOR BioPharma Announces Issuance of European Patent for its LPM 28TM 29 Oral Drug Delivery Technology 12934 5Transdel Pharmaceuticals Completes Enrollment in Phase 3 Clinical Study for Novel Topical Pain Treatment 51043 1Transdel Pharmaceuticals Completes Enrollment in Phase 3 Clinical Study for Novel Topical Pain Treatment 51043 2Transdel Pharmaceuticals Completes Enrollment in Phase 3 Clinical Study for Novel Topical Pain Treatment 51043 3Breakfast Anyone 3F Lifestyle Foods Launches Two Energizing Snacks Containing Under 200 Calories 51041 1Breakfast Anyone 3F Lifestyle Foods Launches Two Energizing Snacks Containing Under 200 Calories 51041 2
...BRUNSWICK, N.J., May 7 Johnson & Johnson,will pro... on Friday, May 9,at 4:00 p.m. (Eastern Time) to c...ual meeting in Tampa, Fla. Phase 3 clinical data p...te release (IR), a novel centrally acting,oral ana...S., A pre-recorded Webcast, with the lead tapenta...
...-Large Study Shows Benefits Differ from those in A...n to,children who are hospitalized for bacterial m...in reduced hospital stays, according to a large,mu...ding stands in contrast,to previous studies in hos...cally reduced mortality., "Because of the demonst...
Other Medicine Technology:Steroids Provide No Survival Benefit for Children With Bacterial Meningitis 2Steroids Provide No Survival Benefit for Children With Bacterial Meningitis 3
(Date:12/1/2009)..., SEATTLE, Dec. 1 Ce... management,s presentation at the 21st Annual Pipe...ber 1 at 11:00 a.m. Eastern Time will be webcast l...sentation will take place in Holmes 1 at the New Y...eplay after the presentation. , , ...
(Date:12/1/2009)...w-dose radiation from annual mammography screening...etic or familial predisposition to breast cancer, ... meeting of the Radiological Society of North Amer...t cancer, screening is very important, but a caref...graphy for screening young women, particularly und...
(Date:12/1/2009)...gh-frequency ultrasound with elastography can help...onditions, according to a study presented today at... North America (RSNA). , "High-frequency ultraso... the efficiency of skin cancer diagnosis," said le...the Department of Radiology at the University of M...
(Date:12/1/2009)...sults of a randomized, controlled clinical trial p...ogical Society of North America (RSNA) reveal that...n arteries that supply blood to the legs and other...t coronary artery disease. , Peripheral arteria...of fat, cholesterol and other substances, builds u...
(Date:12/1/2009)...MO, December 1, 2009 Adolescent obesity is a majo...ery three children, resulting in 4-5 million overw...shed in the December 2009 issue of the Journal of...valuated differences in weight control behaviors, ...mparing overweight adolescents who lost weight and...
Breaking Medicine News(10 mins):Health News:Mammography may increase breast cancer risk in some high-risk women 2Health News:Special ultrasound accurately identifies skin cancer 2Health News:Severe asymptomatic heart disease may accompany narrowing in leg arteries 2Health News:Investigators identify successful weight control strategies for adolescents 2
...ird flu free nation' status next month, as no case...ry for the last three months, federal Agriculture ... has been no case of avian influenza for the last ...nisation for Animal Health (OIE) on August 10. The...
...al of "user charges" at the All India Institute of... notice of the National Human Rights Commission //...ion on the matter. In a letter to NHRC Chairp...ed to withdraw the "users charges" slapped on poor...
...has been advised by experts in respiratory disease...LABA) drugs are dangerous. LABA drugs are// used t...silis Vassiliou, of the University of Cambridge wh...always be used in addition to other steroid drugs ...
...New Zealand is making certain changes to asthma me...anges are bound to benefit// a significant number ... of the changes include widening the access to ast...r Peter Moodie stressed that these changes will wi...
...a Institute of Medical Sciences' (AIIMS) has acqui...sia, to help in delicate surgeries// at the depart...e acquired the Da Vinci Surgical Robot on July 19 ... and head of urology AIIMS. The machine was ...
..., head of the department of gynecology at the Cath...scientists is working on the disease// endometrios... The disease affects women and results in the gr...nfertility. Statistics show that the disease affec...
Other Medicine News:Health News:AIIMS Acquires Four-Armed Robot to Assist in Surgeries 2
Ultra Thin Sheet
Tanne Corneal Cutting Block
Surgical Markers
Periosteal Elevator
Medicine Products: